Akoya Biosciences(AKYA)

Search documents
Akoya Biosciences Reports Third Quarter 2024 Financial Results
GlobeNewswire News Room· 2024-11-14 21:00
MARLBOROUGH, Mass., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced its financial results for the third quarter ending September 30, 2024. "Our third-quarter results came in below expectations, largely due to ongoing capital equipment purchase constraints seen across the life science tools market. We remain optimistic about the long-term growth outlook of our industry, but we recognize the current environment will pose tempora ...
Akoya Bioscience to Report Third Quarter 2024 Financial Results on November 14, 2024
GlobeNewswire News Room· 2024-10-28 12:30
MARLBOROUGH, Mass., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the third quarter of 2024 after the market closes on Thursday, November 14, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advanc ...
Akoya's Leading Spatial Proteomics Platforms Selected for Use by Ground-Breaking UK-Based MANIFEST Consortium to Revolutionize Cancer Immunotherapy
GlobeNewswire News Room· 2024-10-07 12:00
Consortium includes top universities, hospitals and industry partners, led by the Francis Crick Institute and The Royal Marsden NHS Foundation Trust Akoya's platforms will be used for deep spatial proteomic profiling of thousands of tissue samples from cancer patients to identify biomarkers predicting treatment success MARLBOROUGH, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), The Spatial Biology Company®, today announced that the company's PhenoCycler® Fusion an ...
Akoya Biosciences Announces Scott Mendel as Chairman of the Board of Directors
GlobeNewswire News Room· 2024-10-03 20:00
MARLBOROUGH, Mass., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) ("Akoya"), the Spatial Biology Company®, today announced Scott Mendel has been appointed as Chairman of its Board, effective October 2, 2024. Mr. Mendel succeeds Robert Shepler, founding Chairman, who will remain on Akoya's board. Mr. Mendel has served as a member of Akoya's board of directors since June 2021 and has over 30 years of financial and operational management experience. "I am thrilled to continue working ...
Akoya Biosciences(AKYA) - 2024 Q2 - Earnings Call Transcript
2024-08-06 02:19
Akoya Biosciences, Inc. (NASDAQ:AKYA) Q2 2024 Earnings Conference Call August 5, 2024 5:00 PM ET Corporate Participants Priyam Shah - Head, Investor Relations Brian McKelligon - Chief Executive Officer Johnny Ek - Chief Financial Officer Conference Call Participants William Bonello - Craig-Hallum Kyle Mikson - Canaccord Tejas Savant - Morgan Stanley David Westenberg - Piper Sandler Rachel Vatnsdal - JPMorgan Ricki Levitus - Guggenheim Vivian Bais - BTIG Tim Cheung - Capital One Mason Carrico - Stephens Oper ...
Akoya Biosciences(AKYA) - 2024 Q2 - Quarterly Report
2024-08-05 21:36
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-40344 Akoya Biosciences, Inc. (Exact name of registrant as specified in its charter) Dela ...
Akoya Biosciences(AKYA) - 2024 Q2 - Quarterly Results
2024-08-05 20:07
● For the second quarter of 2024, revenue was $23.2 million, a 26.2% quarter- over-quarter increase from $18.4 million in the first quarter and 1.5% year-over- year decrease from $23.5 million in the second quarter of 2023. o Instruments, consumables and services all contributed to sequential growth. Instrument revenue was $8.3 million, a 70.4% quarter-over- quarter increase. Reagent revenue was $7.4 million, a 5.6% quarter- over-quarter increase. Service and other revenue was $7.2 million, a 16.6% quarter- ...
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
Newsfilter· 2024-07-15 20:00
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (NASDAQ:AKYA) ("Akoya"), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A ...
Akoya Biosciences to Report Second Quarter 2024 Financial Results on August 5, 2024, and Participate at Two Upcoming Investor Conferences
GlobeNewswire News Room· 2024-07-15 20:00
MARLBOROUGH, Mass., July 15, 2024 (GLOBE NEWSWIRE) -- Akoya Biosciences, Inc. (Nasdaq: AKYA) (“Akoya”), The Spatial Biology Company®, today announced that it will release financial results for the second quarter of 2024 after the market closes on Monday, August 5, 2024. Company management will host a conference call to discuss financial results at 5:00 p.m. ET. Investors interested in listening to the conference call are required to register online. It is recommended to register at least a day in advance. A ...
Lab Instrument Industry Update - New Commercial Entrants
seekingalpha.com· 2024-05-23 13:17
nicolas_Introduction I believe one of the best sectors of the healthcare industry is the Lab Instrument and Services providers who can generate high recurring revenues from small amounts of instrument sales. Examples include research focused Thermo Fisher (TMO) and Danaher (DHR), along with diagnostics providers such as Qiagen (QGEN) and Revvity (RVTY). I have discussed the opportunity in these names recently as the healthcare industry is facing immense headwinds not seen since major recessions. As such ...